0001213900-23-056204.txt : 20230711 0001213900-23-056204.hdr.sgml : 20230711 20230711161529 ACCESSION NUMBER: 0001213900-23-056204 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230711 DATE AS OF CHANGE: 20230711 EFFECTIVENESS DATE: 20230711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MAINZ BIOMED N.V. CENTRAL INDEX KEY: 0001874252 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-486514 FILM NUMBER: 231082285 BUSINESS ADDRESS: STREET 1: ROBERT KOCH STRASSE 50 CITY: MAINZ STATE: 2M ZIP: 55129 BUSINESS PHONE: 49 6131 5542860 MAIL ADDRESS: STREET 1: ROBERT KOCH STRASSE 50 CITY: MAINZ STATE: 2M ZIP: 55129 FORMER COMPANY: FORMER CONFORMED NAME: Mainz Biomed B.V. DATE OF NAME CHANGE: 20210721 D 1 primary_doc.xml X0708 D LIVE 0001874252 MAINZ BIOMED N.V. ROBERT KOCH STRASSE 50 MAINZ 2M GERMANY 55129 +49-6131-55428-60 NETHERLANDS None Mainz Biomed B.V. Corporation true 2021 William Caragol Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Executive Officer Guido Baechler Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Executive Officer Director Moritz Eidens Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Executive Officer Director Heiner Dreismann Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Director Nicole Holden Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Director Hans Hekland Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Director Alberto Libanori Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Director Phillip Freese Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Executive Officer Darin Leigh Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Executive Officer Gregory Tibbits Robert Koch Strasse 50 c/o Mainz Biomed N.V. Mainz 2M GERMANY 55129 Director Biotechnology Decline to Disclose 06b false 2023-06-28 false true true true true false 0 50000000 5500000 44500000 $5.5M ordinary shares per a Pre-Paid Advance Agreement via convertible promissory note into 2.75K ordinary shares exercisable at lower of $4.9986 or 92% of the avg. of the 2 lowest daily VWAPs during 8 trading days prior to conversion with $2 floor price. false 1 0 0 0 true false MAINZ BIOMED N.V. /s/ William J. Caragol William J Caragol Chief Financial Officer 2023-07-11